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the efficacy of RhoA and Rho kinase inhibitors in
animal models of ischaemic stroke
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Abstract
Background: There is currently only one clinically approved drug, tissue plasminogen activator (tPA), for the
treatment of acute ischaemic stroke. The RhoA pathway, including RhoA and its downstream effector Rho kinase
(ROCK), has been identified as a possible therapeutic target. Our aim was to assess the impact of study design
characteristics and study quality on reported measures of efficacy and to assess for the presence and impact of
publication bias.
Methods: We conducted a systematic review and meta-analysis on publications describing the efficacy of RhoA
and ROCK inhibitors in animal models of focal cerebral ischaemia where outcome was assessed as a change in
lesion size or neurobehavioural score, or both.
Results: We identified 25 published papers which met our inclusion criteria. RhoA and ROCK inhibitors reduced
lesion size by 37.3% in models of focal cerebral ischaemia (95% CI, 28.6% to 46.0%, 41 comparisons), and reduced
neurobehavioural data by 40.5% (33.4% to 47.7%, 30 comparisons). Overall study quality was low (median=4,
interquartile range 3–5) and measures to reduce bias were seldom reported. Publication bias was prevalent and
associated with a substantial overstatement of efficacy for lesion size.
Conclusions: RhoA and ROCK inhibitors appear to be effective in animal models of stroke. However the low quality
score, publication bias and limited number of studies are areas which need attention prior to conducting clinical
trials.
Keywords: Meta-analysis, Ischaemic stroke, ROCK inhibitors, RhoA inhibitors, Publication bias, Study quality,
Systematic review, Animal studies
Background
Ischaemic stroke is responsible for substantial death and
disability worldwide [1]. Tissue plasminogen activator
(tPA) is the only biological intervention used in routine
clinical practice in the treatment of acute ischaemic
stroke, albeit in a select cohort of patients. Potential
neuroprotective drugs that show efficacy in animal
models that have been brought forward to clinical trials
(for example, tirilazad and NXY-059) have subsequently
failed to replicate this efficacy in humans [2-4]. New ef-
fective therapies to treat ischaemic stroke are urgently
required.
The Rho kinase pathway is closely related to the
pathogenesis of several CNS disorders and has been
proposed as an attractive target in the treatment of is-
chaemic stroke [5]. Rho-GTPases (including RhoA, Rac1
and Cdc42) play a major role in the regulation of many
cell behaviours [6]. Rho-associated kinase (ROCK) is a
major downstream effector of the GTP-bound form of
RhoA [7] and is associated with a range of intracellular
signalling pathways including a reduction in endothelial
nitric oxide synthase (eNOS) expression. Putative ROCK
inhibition mediated neuroprotection is hypothesised to
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occur, in part at least, due to increased eNOS expression
that increases the production of the potent vasodilator
nitric oxide and thus increases cerebral blood flow, in-
cluding collateral flow to the ischaemic area [8].
Fasudil is a ROCK inhibitor that is in clinical use for
cerebral vasospasm after subarachnoid haemorrhage [9].
It has been shown to be safe and effective in a clinical
trial involving 160 patients when administered intraven-
ously within 48 h of ischaemic stroke onset [10]. How-
ever, this trial was limited in sample size and outcomes
were assessed at just 1-month follow-up. The evidence
of safety and potential efficacy makes fasudil and
other ROCK inhibitors ideal candidates for further
investigation.
Systematic review and meta-analysis of preclinical data
are becoming increasingly common. They provide useful
summaries which can be used to inform clinical trial de-
sign, highlight areas which may benefit from further pre-
clinical research, and provide insights into the reasons
for translational failures [11,12]. Prior to conducting a
clinical trial, these techniques should be used to assess
whether efficacy has been achieved in high quality, prag-
matically designed studies which adequately reflect the
human sample (for example, aged population with co-
morbidities) and the treatment paradigm which can be
achieved (for example, later times to treatment) [13].
Our aim was to assess the impact of study design char-
acteristics and study quality on the reported measures
of efficacy in a systematic review and meta-analysis of
RhoA and ROCK inhibitors tested in animal models
of focal cerebral ischaemia to inform both the design of
clinical trials and, if required, further preclinical experi-
ments. Specifically our objectives were to: (1) identify
relevant publications and describe the scope of the
literature; (2) report summary estimates of efficacy; (3)
assess the impact of reported study quality checklist
items and study design on estimates of efficacy; and (4)
assess for the presence and impact of any publication bias.
Methods
All of our methods were pre-specified in a study proto-
col which can be accessed at http://camarades.info/
index_files/Protocols.html.
Search strategy
We electronically searched three online databases
(Pubmed, Web of Knowledge and EMBASE) in Septem-
ber 2012, using the following search terms: ((C3) OR
(C3-transferase) OR (Y27632) OR (Y-27632) OR (non-
steroidal anti-inflammatory) OR (NSAID) OR (ibupro-
fen) OR (Rho kinase) OR (rho-kinase) OR (rho) OR
(ROCK) OR (RhoA) OR (Fasudil) OR (HA-1077) OR
(HA 1077) OR (HA1077) OR (cethrin) OR (BA-210))
AND ((stroke) OR (ischemia) or (ischaemia) OR (middle
cerebral artery) OR (cerebrovascular) OR (MCA) OR
(ACA) OR (anterior cerebral artery) OR (MCAO)) NOT
(coronary) OR (myocardia*)). Results were limited to an-
imals. Additionally, the Web of Knowledge search was
also refined by excluding reviews, books, letters, clinical
trials, case reports, patents and editorials. Abstracts were
independently screened by two reviewers (GC and ES)
to identify those meeting our inclusion criteria (see
below), with differences resolved by discussion with a
third reviewer (HV and RW).
Inclusion criteria and data extraction
We included studies which reported the effects of inhibi-
tors known to directly inhibit RhoA or ROCK in an
in-vivo animal model of focal cerebral ischemia. We did
not include studies which reported the effects of drugs
known to inhibit molecules in the Rho pathway up-
stream of RhoA and ROCK. We included studies that
reported the number of animals per group, outcome as a
lesion size (infarct volume or infarct area; primary out-
come) or a neurobehavioural score (secondary outcome)
or both, and the mean and its variance (standard error
of the mean (SEM) or standard deviation (SD)). Experi-
ments with co-treatments were excluded. Data were
extracted to the CAMARADES data manager.
Quality assessment
We assessed studies against the CAMARADES 10-item
quality check list [12]. One point was awarded for each
of: (1) publication in a peer-reviewed journal; and
reporting of: (2) control of temperature, (3) random
allocation to groups, (4) allocation concealment, (5)
blinded assessment of outcome, (6) use of an anaesthetic
without intrinsic neuroprotective activity, (7) the use of
co-morbid animals, (8) performing a sample size calcula-
tion, (9) compliance with animal welfare regulations,
(10) a statement of potential conflicts of interest.
Data extraction
We extracted data on study design including the time,
route and dose of the drug administration, the species,
sex and strain of the animal, the type of ischaemia (per-
manent, temporary or thrombotic), the anaesthetic and
ventilation method used during the induction of injury
and the method of quantification of lesion size.
For each comparison on drug efficacy we extracted
data on the number of animals per group, the mean out-
come and the variance for both the control and treat-
ment group. When a single control group was used for
multiple treatment groups this was adjusted by dividing
by the number of treatment groups served. Where data
were not reported we made efforts to contact authors.
Where data were reported graphically we used digital
ruler software (Universal Desktop Ruler) and where data
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were expressed serially we extracted the final time point.
Where it was not clear if the measure of variance was
SD or SEM we extracted data as SEM, as for the pur-
pose of meta-analysis this is a more conservative
estimate.
All data were extracted by a single, non-blinded,
reviewer.
Data analysis
We deemed infarct volume and area to be sufficiently
similar to be grouped into the same meta-analysis which
we refer to as lesion size. We calculated a normalised
mean difference effect size for each comparison
(Vesterinen et al., manuscript in preparation) and com-
bined these in a weighted mean difference meta-analysis
using the random effects model [14]. Where different
measures of neurobehavioural outcome were reported
from the same cohort of animals we combined individ-
ual effect sizes (pre-nested comparisons) using fixed ef-
fects meta-analysis (nesting) and used this summary
estimate in the random effects model.
We used stratified meta-analysis to assess for the im-
pact of drug dose, time of administration, blinded assess-
ment of outcome, random allocation to group, the
overall study quality score, type of ischaemia, the sex
and species of animal used, anaesthetic used and use
of mechanical ventilation; and for infarct volume we
additionally analysed the method of quantification.
The significance of differences between n groups was
assessed by partitioning heterogeneity and by using the
χ2 distribution with n-1 degrees of freedom (df). To
allow for multiple comparisons we adjusted our signifi-
cance level using Bonferroni correction to a critical value of
P <0.004 for each of infarct volume and neurobehavioural
scores.
Publication bias was assessed using funnel plotting
[15], Egger regression [16] and trim and fill [17].
Results
We identified 3,286 publications in our electronic search
of which 3,237 were excluded in the first instance (513
duplicates and 2,724 publications which did not meet
our inclusion criteria). We screened 49 publications in
detail from which we excluded a further 24 publications
(16 had no relevant outcome measures; four only
reported outcomes measured outside the brain; two
were abstracts later published in full; one did not use a
relevant intervention; and one was a review).
Our systematic review therefore included 25 articles
published between 1992 and 2011 which met our inclu-
sion criteria (24 full publications and one conference
abstract; Additional file 1). We extracted data for 41
comparisons describing infarct volume from 23 publica-
tions and 30 nested comparisons (32 pre-nested) were
extracted for neurobehavioural scores from 18 publica-
tions (Figure 1).
We identified five different interventions: fasudil (20
publications), ibuprofen (3), Y-27632 (2), clostridium
boulinum C3 transferase (1) and flurbiprofen (1). These
were tested in rats (17 publications), mice (6), dogs (1)
and gerbils (1). Experiments most commonly used male
animals (14 publications); one publication used both
males and females and five publications did not report
the sex of the animals.
Models of transient ischaemic stroke were most com-
monly used (14 publications); permanent and thrombo-
embolic models of ischaemia were both used in six
publications each. Three studies reported the use of
mechanical ventilation during anaesthesia, spontaneous
ventilation was reported in 13 publications, and the
method could not be determined in nine publications.
Interventions were most often administered via the
intra-peritoneal injection (14 publications), followed
by intravenous (5), subcutaneous (2), and intra-
cerebroventricular and intracoronary injection were
both described in one publication each and the single
conference abstract did not state the route of adminis-
tration used.
Timing of drug administration ranged from 2 weeks
prior to and 48 h after the induction of ischaemia. For
43 unique cohorts of animals, 24% of studies adminis-
tered the intervention at the same time as the induction
of ischaemia which was the most common time point.
The time of assessment ranged from 5 h to 29 days after
induction of ischaemia with 40% assessing outcome at
the most common time point, 24 h.
Global estimates of efficacy
RhoA and ROCK inhibitors reduced lesion size by 37.3%
in models of focal cerebral ischemia (95% confidence
interval (CI), 28.6% to 46.0%, 41 comparisons; Figure 2A).
Heterogeneity was high reflecting anticipated differences
between studies (Χ2=232.4, I2=83%, P=9x10-30). RhoA
and ROCK inhibitors improved neurobehavioural out-
come by 40.5% (95% CI 33.4% to 47.7%, 30 comparisons;
Figure 2B). Heterogeneity between studies reporting
neurobehavioural scores was low and not significant and
therefore we did not explore this further (Χ2=39.6,
I2=27%, P=0.09).
Publication bias
Visual inspection of a funnel plots suggested a substan-
tial publication bias for both infarct volume and
neurobehavioural outcomes which was supported by
Egger regression. Trim and fill predicted 10 theoretical
missing studies measuring infarct volume, and taking
these into account, reduced efficacy from 37.3% (28.6-
46.0) to 28.6% (20.0-37.1) for 51 outcomes (relative
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overstatement of efficacy, 26.4% and absolute overstate-
ment of efficacy, 8.7%; Figure 3). Trim and fill did not
predict any theoretical missing studies measuring
neurobehavioural scores.
Study quality
For the 25 publications included in the systematic re-
view, 24 were published in a peer-reviewed journal
(96%), 10 reported that they randomly allocated ani-
mals to treatment groups (40%); seven report blinding
their assessment of outcome (28%); seven report allo-
cation concealment (28%); 16 report controlling the
temperature of the animals during the induction of
ischaemia (64%); 22 used an anaesthetic without intrin-
sic neuroprotective properties (88%); 14 report compli-
ance with animal welfare regulations (56%); one used
animals with co-morbidities (spontaneously hyperten-
sive rats, 4%); one reported a statement of a potential
conflict of interest (4%) and no publications used a
sample size calculation (Additional file 2).
Sample sizes were small, for lesion size the median
number of animals per group was 5 in the control group
(IQR 3 to 10) and 10 in the treatment group (8 to 10);
and for neurobehavioural outcomes, the median number
in the control group was 6 (3 to 10) and 10 in the treat-
ment group (8 to 10).
Overall, the median study quality score was 4 (IQR
3–5). Stratifying by the overall quality score accounted
for a significant proportion of between study heterogen-
eity for lesion size; however the trend was not clear
(Figure 4A). There were no significant effects of random
allocation to group, allocation concealment, blinded
assessment or control of temperature.
Study characteristics
Taking all drugs together, we found that effect sizes were
greater in studies where thrombotic models of ischaemia
were used compared to transient and permanent models
(X2=17.2, df=2, P=0.0002; Figure 4B; Additional file 3),
when pentobarbital anaesthesia was used during the
induction of ischaemia (X2=18.7, df=5, P=0.0009;
Figure 1 PRISMA flow diagram. The progression from the literature search to the meta-analysis showing the number of exclusions from the
initial literature search.
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Figure 4C); when the drug was administered between 5
and 10 min after the induction of ischaemia (X2=42.7,
df=3, P=2.85×10-9; Figure 4D); and in studies where
both male and female animals were used (X2=20.1,
df=2, P=4.26×10-5; Figure 4F).
We analysed the dose response of fasudil separately
and found that the median dose tested was 10 mg/kg
(IQR 1.5-10) for 27 cohorts in which infarct volume was
measured. Furthermore efficacy was highest when ad-
ministered at a dose of 10mg/kg (X2=40.5, df=2,
P=1.62×10-9; Figure 4E).
Stratifying the data according to the species of animal,
the type of ventilation and method used to quantify
lesion size had no significant effect on the percentage
improvement in lesion size.
Discussion
Rho GTPase Kinase inhibitors appear to have a substan-
tial impact in both reducing lesion size and improving
neurobehavioral scores in animal models of stroke.
However, although these results are initially encouraging
they should be interpreted with caution due to both the
limitations within the included studies and of the
present study. These are discussed below.
Study quality
Our study quality checklist assesses aspects of both in-
ternal and external validity, and we have frequently ob-
served studies of poorer methodological quality tending
to overstate effect sizes [2,18]. Here we found that stud-
ies were generally of low quality (median 4 out of 10).
Figure 2 Effect sizes of included comparisons. A timber plot of the effect sizes for each of the comparisons measuring infarct volume (A) and
neurobehavioural scores (B). Error bars represent 95% confidence intervals (CI).
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Specifically, measures to reduce bias including blinded
induction of ischaemia, random allocation to group and
blinded assessment of outcome were all seldom reported
in this dataset. The overall quality score accounted for a
significant proportion of between study heterogeneity;
however, a correlation between the aggregate quality
score and effect was not clear.
Study design
We found that RhoA and ROCK inhibitors were most
efficacious when administered between 5 and 10 min
after the induction of ischaemia and encouragingly
sustained efficacy up to 48 h post injury. This is espe-
cially relevant as the median time for stroke patients to
arrive at hospital is 4.3 h [19]. The high efficacy at later
time points reflects what was achieved in a double-
blind, placebo-controlled clinical trial of fasudil where
it was administered up to 48 h after ischaemic stroke
[10]. In addition we found that efficacy of fasudil was
greatest with doses of 10 mg/kg; however in the clin-
ical trial of fasudil the dose used was 60 mg which
equates to roughly 1 mg/kg and this was administered
intravenously whereas the most frequent route of de-
livery was intraperitoneal in the preclinical literature.
To our knowledge, this is the only clinical trial of a
RhoA or ROCK inhibitor in ischaemic stroke; fasudil
significantly improved neurological scores at 2 weeks
and clinical outcomes at 1 month. Larger trials with
longer follow-up times will further elucidate whether
fasusdil is a viable candidate stroke treatment.
We also found that efficacy was highest when both
males and females were used in the same experiment,
and when the induction of ischaemia was performed
under pentobarbital anaesthesia. Importantly, pentobar-
bital has shown neuroprotective activity in preclinical
studies of ischaemia which confounds our interpretation
of the efficacy of fasudil under its use [20].
Efficacy was also higher in thrombotic and temporary
models. The ischaemic model may be of particular inter-
est because the proposed mechanism of action of RhoA
and ROCK inhibitors is by increasing vasodilation and
therefore increasing cerebral blood flow. Therefore it is
conceivable that this class of intervention would be of
no benefit in permanent ischaemia.
Figure 3 Publication bias. Funnel plots (A and B) and egger regression (C and D) for infarct volume (A and C) and neurobehavioural scores
(B and D). Red symbols in (A) represent theoretical missing studies identified using ‘trim and fill’.
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Across several datasets on preclinical models of stroke,
roughly 10% of studies use animals with co-morbidities
relevant to stroke patients, such as hypertension and
diabetes [12]. In our dataset, one publication used spon-
taneously hypertensive rats; no other publication out of
25 used animals with a co-morbidity. This may limit the
predictive value of these studies for clinical trials. Fur-
thermore co-morbidities can affect efficacy in animal
models [21].
Relevance to the clinical setting
Nearly all interventions which have shown promise in
preclinical studies have failed to translate successfully to
the clinical setting [22]. Systematic review and meta-
analysis of the preclinical literature on a number of these
candidate interventions have shown that compromised
internal validity and external validity may be a crucial
factor in the failure to translate efficacy. For example,
careful inspection of the preclinical literature on NXY-
Figure 4 Impact of study design characteristics. The effect of the aggregate quality score (A), type of ischaemia (B), anaesthetic used during
the induction of ischaemia (C), the time of administration (D), the drug dose (E) and the sex of the animals (F) on the estimates of efficacy
measured as improvement in lesion size. Error bars represent 95% CI and bar widths represent the log of the number of animals. The horizontal
error bar represents the global estimate of efficacy for lesion size and its 95% CI.
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059 identified that efficacy was substantially greater in
studies which did not report allocation concealment,
random allocation to group or blinded assessment of
outcome [2]; moreover, NXY-059 failed to show im-
provement in a phase II clinical trial [23]. Of concern,
we have no reason to believe that the studies included in
this study are of greater quality; the median quality score
of nine publications testing NXY-059 was 5, compared
to 4 for RhoA and ROCK inhibitors.
Limitations
The present study provides a useful summary of the pre-
clinical data on RhoA and ROCK inhibitors. However
there are limitations to our approach and the results
should therefore be interpreted with caution. First, al-
though our search strategy was designed to be robust,
we cannot rule out the possibility of missing studies.
Furthermore, this may also be due to publication bias.
Similar to our previous findings [24], we found that
publication bias was prevalent in this dataset. Although
our dataset was relatively small, we used three ap-
proaches to minimise the risk of confounding; indeed the
more conservative trim and fill approach did not identify
any theoretical missing studies for neurobehavioral out-
comes. Taking into account theoretical missing studies, our
estimates of efficacy are likely to be overstated.
Second, we found that the heterogeneity between stud-
ies reporting neurobehavioural outcomes was unusually
low. Although this may be a true reflection of an under-
lying treatment effect which was the same across studies,
in our experience this is a rare occurrence, especially in
preclinical literature. We found that articles were pub-
lished between 1994 and 2011 and were from 14 unique
research groups with a number of different scoring
methods used including the postural reflex score (one
publication), 5-point scales (four publications). However
visual inspection of the timber plot for neurobehavioural
outcome (Figure 2B) confirms that there was very little
heterogeneity with overlapping confidence intervals for
nearly all of the comparisons.
Third, grouping together data from different studies
may mask subtle but relevant differences in efficacies. In
particular, we have grouped together five different drugs
within this class since there were too few comparisons
to assess them separately.
Conclusions
Our analyses suggest that RhoA and ROCK inhibitors
may be a useful drug class for further preclinical re-
search. Reported efficacy was high across both outcome
measures; however heterogeneity between studies was
high where efficacy was measured as a change in lesion
size. We have provided details of the conditions under
which these drugs performed optimally; these include
using a thrombotic model, pentobarbital anaesthesia, ad-
ministering the intervention between 5 and 10 min post
induction and at a dose of 10 mg/kg and when both
male and female animals were used. However low study
quality scores and the lack of animals with co-morbidities
are confounding factors. Finally this analysis highlights
the need for further high quality, pragmatically designed
studies which will shed light on the therapeutic potential
of RhoA and ROCK inhibitors in a clinical setting.
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